Get the Stockscreener App
5.435
4.65%
-0.265
After Hours:
5.43
-0.005
-0.09%
Yd Bio Ltd stock is traded at $5.435, with a volume of 31,613.
It is down -4.65% in the last 24 hours and down -25.55% over the past month.
YD Bio Ltd is a biopharmaceutical company focusing on blood-based cancer detection, the development of stem cell- and exosome-based therapeutics with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need and serving as a trusted supplier of clinical testing drugs for pharmaceutical companies. Stem cell therapy uses versatile cells to repair or regenerate damaged tissues, offering innovative treatments for injuries, degenerative diseases, and immune disorders with potential for personalized medicine and tissue engineering.
See More
Previous Close:
$5.70
Open:
$5.77
24h Volume:
31,613
Relative Volume:
1.16
Market Cap:
$383.28M
Revenue:
-
Net Income/Loss:
$-2.97M
P/E Ratio:
-5.501
EPS:
-0.988
Net Cash Flow:
$-1.18M
1W Performance:
-5.64%
1M Performance:
-25.55%
6M Performance:
-71.20%
1Y Performance:
+0.00%
1-Day Range:
$5.20
$5.77
1-Week Range:
$5.12
$6.49
52-Week Range:
$5.12
$25.00
Yd Bio Ltd Stock (YDES) Company Profile
Compare YDES vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
YDES
Yd Bio Ltd
|
5.435 | 401.97M | 0 | -2.97M | -1.18M | -0.988 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Yd Bio Ltd Stock (YDES) Latest News
YDES Technical Analysis & Stock Price Forecast - Intellectia AI
YDES SEC FilingsYD Bio Ltd 10-K, 10-Q, 8-K Forms - Stock Titan
YD Bio (YDES) director receives $60,000 RSU grant and 2,081 shares - Stock Titan
Director at YD Bio (YDES) receives $60K RSU equity award - Stock Titan
YD Bio (NASDAQ: YDES) director Lu Shao-Ta files initial Form 3 - Stock Titan
Director Chang Kochi logs initial insider status at YD Bio Ltd (YDES) - Stock Titan
YD Bio launches telehealth platform for cancer detection By Investing.com - Investing.com South Africa
YD Bio launches telehealth platform for cancer detection - Investing.com
YD Bio and EG BioMed Jointly Launch Nationwide Telehealth Platform to Accelerate Commercialization of Cancer Detection and Decentralized Clinical Services Across the United States - The Manila Times
Yd Bio Limited and Eg Biomed Co., Ltd. Launch Nationwide Telehealth Platform - marketscreener.com
YD Bio (YDES) director files Form 3 with no share activity - Stock Titan
Stock List: Research Stocks from Around the World - GuruFocus
[Form 3] YD Bio Ltd Initial Statement of Beneficial Ownership - Stock Titan
[Form 3] YD Bio Ltd Initial Statement o... - Stock Titan
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
YD Bio details roadmap for integrated oncology ecosystem - tipranks.com
YD Bio (YDES) CEO details direct and indirect share stakes - Stock Titan
Collective Metals Initiates Inaugural Drill Program at the Rocas Uranium Project in Southeast Athabasca Basin - The Manila Times
YD Bio Limited CEO Dr. Ethan Shen Details Strategic Roadmap for Integrated Oncology Ecosystem - Bitget
Inside YD Bio’s plan to link cancer detection with immunotherapy - Stock Titan
Entrada Therapeutics (NASDAQ:TRDA) Stock Rating Upgraded by Wall Street Zen - Defense World
NMFC PE Ratio & Valuation, Is NMFC Overvalued - Intellectia AI
Vir Biotechnology (NASDAQ:VIR) Stock Rating Upgraded by Wall Street Zen - Defense World
YD Bio (NASDAQ: YDES) registers 11.5M warrant shares; announces Taiwan-U.S. FDA alliance - Stock Titan
YD Bio Forms Taiwan-U.S. Dual-Core FDA Regulatory Platform in Alliance with YC Biotech - TipRanks
YD Bio (Nasdaq: YDES) builds Taiwan-U.S. FDA regulatory platform - Stock Titan
YD Bio partners with YC Biotech to establish Taiwan-US dual-core regulatory platform - BioSpectrum Asia
YD Bio Says US Unit Selected as FDA Liaison for YC Biotech's Asia Clients - marketscreener.com
Yd Bio Limited announces strategic partnership with Yc Biotech Co - marketscreener.com
SunPower to Participate in the 38th Annual ROTH Conference - The Manila Times
Rumble App Now Includes Rumble Shorts on iPhones Following Apple Approval - The Manila Times
The Chefs’ Warehouse, Inc. to Participate in the UBS Global Consumer & Retail Conference - The Manila Times
Freshworks to Participate in Upcoming Investor Conferences - The Manila Times
The Oncology Institute to Participate in Multiple Healthcare Investor Conferences in March - The Manila Times
Elicio Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference - The Manila Times
Prime Medicine to Participate in Upcoming Investor Conferences - The Manila Times
Major Shareholder Announcement - The Manila Times
YD Bio Limited Announces Strategic Partnership with YC Biotech Co., Ltd. to Establish a Taiwan-U.S. Dual-Core Regulatory Platform - marketscreener.com
Inside YD Bio’s new Taiwan‑U.S. gateway for FDA drug and device approvals - Stock Titan
YDESYD Bio Ltd Latest Stock News & Market Updates - Stock Titan
Ethan Shen holds 77.06% of YD Bio Ltd (YDES) as amended ownership filing - Stock Titan
YD Bio Ltd (YDES) PE Ratio (TTM) Chart - GuruFocus
YD Bio Shares Spark Retail Trader Buzz Following Nasdaq Debut via Breeze SPAC - MSN
CMB.TECH to Release Q4 2025 Earnings on February 26, 2026 - Intellectia AI
CMB.TECH Sells Two VLCCs, Realizing $98.2 Million Gain - Intellectia AI
Weekly Buzz: Intellia Gets FDA Nod For ATTRv-PN Trial; Aprea's APR-1051 Paces; CALC Halts KOURAGE - RTTNews
YD Bio Signs Binding LOI to Acquire Taiwan Immunotherapy Firm SSMC - TipRanks
YD Bio to acquire Taiwan’s SSMC for $26.87 million By Investing.com - Investing.com Nigeria
YD Bio to acquire Taiwan’s Safe Save Medical in $26.9 million deal By Investing.com - Investing.com South Africa
YD Bio to acquire Taiwan’s Safe Save Medical in $26.9 million deal - Investing.com Canada
YD Bio Signs LOI To Acquire Safe Save Medical, Expanding Immunocell Therapy Leadership - Nasdaq
Yd Bio Ltd Stock (YDES) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):